^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    JS203

    i
    Other names: JS203
    Associations

    News

    Trials
    Company:
    Shanghai Junshi Biosci
    Drug class:
    CD20 inhibitor, CD3 agonist
    Related drugs:
    Associations

    News

    Trials
    9ms
    Phase I Clinical Study of JS203 in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P1, N=219, Recruiting, Shanghai Junshi Bioscience Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD20 (Membrane Spanning 4-Domains A1) • IL6 (Interleukin 6) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
    |
    CD20 expression
    |
    JS203
    over1year
    Phase I Clinical Study of JS203 in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P1, N=219, Not yet recruiting, Shanghai Junshi Bioscience Co., Ltd.
    New P1 trial
    |
    CD20 (Membrane Spanning 4-Domains A1) • IL6 (Interleukin 6) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
    |
    CD20 expression
    |
    JS203